Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-κB signaling in PMA-stimulated THP-1 monocytes

Biomedicine and Pharmacotherapy

Volumn 82, Issue , 2016, Pages 167-172

  Kong, Fanqi ^a   Ye, Bozhi ^a   Lin, Lu ^a   Cai, Xueli ^a   Huang, Weijian ^a   Huang, Zhouqing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Atorvastatin; Monocytes; NLRP3 inflammasome; TLR4 MyD88 NF B

Indexed keywords

ATORVASTATIN; CRYOPYRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; NLRP3 PROTEIN, HUMAN; PHORBOL 13 ACETATE 12 MYRISTATE;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

APOPTOSIS; ATORVASTATIN CALCIUM; CELL LINE; CELL SURVIVAL; HUMANS; INFLAMMASOMES; MACROPHAGES; MONOCYTES; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; TOLL-LIKE RECEPTOR 4;

EID: 84965010073     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.04.043     Document Type: Article

References (35)

1. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
2. Woollard K.J., Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat. Rev. Cardiol. 2010, 7:77-86.
3. Imhof B.A., Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat. Rev. Immunol. 2004, 4:432-444.
4. Osterud B., Bjorklid E. Role of monocytes in atherogenesis. Physiol. Rev. 2003, 83:1069-1112.
5. Ley K., Miller Y.I., Hedrick C.C. Monocyte and macrophage dynamics during atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1506-1516.
6. Elhage R., Maret A., Pieraggi M.T., Thiers J.C., Arnal J.F., Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 1998, 97:242-244.
7. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., Abela G.S., Franchi L., Nunez G., Schnurr M., Espevik T., Lien E., Fitzgerald K.A., Rock K.L., Moore K.J., Wright S.D., Hornung V., Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
8. Lamkanfi M., Kanneganti T.D. Nlrp3: an immune sensor of cellular stress and infection. Int. J. Biochem. Cell Biol. 2010, 42:792-795.
9. Stutz A., Golenbock D.T., Latz E. Inflammasomes: too big to miss. J. Clin. Invest. 2009, 119:3502-3511.
10. Menu P., Vince J.E. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin. Exp. Immunol. 2011, 166:1-15.
11. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
12. Rajamaki K., Lappalainen J., Oorni K., Valimaki E., Matikainen S., Kovanen P.T., Eklund K.K. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5:e11765.
13. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005, 45:89-118.
14. Ii M., Losordo D.W. Statins and the endothelium. Vascul. Pharmacol. 2007, 46:1-9.
15. Zhao G., Yu Y.M., Kaneki M., Bonab A.A., Tompkins R.G., Fischman A.J. Simvastatin reduces burn injury-induced splenic apoptosis via downregulation of the TNF-alpha/NF-κB pathway. Ann. Surg. 2015, 261:1006-1012.
16. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.
17. Tsuchiya S., Kobayashi Y., Goto Y., Okumura H., Nakae S., Konno T., Tada K. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res. 1982, 42:1530-1536.
18. Huang Z., Wang L., Meng S., Wang Y., Chen T., Wang C. Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages. Int. J. Cardiol. 2011, 146:153-158.
19. Bauernfeind F.G., Horvath G., Stutz A., Alnemri E.S., MacDonald K., Speert D., Fernandes-Alnemri T., Wu J., Monks B.G., Fitzgerald K.A., Hornung V., Latz E. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 2009, 183:787-791.
20. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
21. Boyle J.J. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr. Vasc. Pharmacol. 2005, 3:63-68.
22. Zheng F., Xing S., Gong Z., Mu W., Xing Q. Silence of NLRP3 suppresses atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice. Mediators Inflamm. 2014, 2014:507208.
23. Luo B., Li B., Wang W., Liu X., Liu X., Xia Y., Zhang C., Zhang Y., Zhang M., An F. Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc. Drugs Ther./Spons. Int. Soc. Cardiovasc. Pharmacother. 2014, 28:33-43.
24. Liao Y.H., Lin Y.C., Tsao S.T., Lin Y.C., Yang A.J., Huang C.T., Huang K.C., Lin W.W. HMG-CoA reductase inhibitors activate caspase-1 in human monocytes depending on ATP release and P2 × 7 activation. J. Leukoc. Biol. 2013, 93:289-299.
25. Xu J.F., Washko G.R., Nakahira K., Hatabu H., Patel A.S., Fernandez I.E., Nishino M., Okajima Y., Yamashiro T., Ross J.C., Estepar R.S., Diaz A.A., Li H.P., Qu J.M., Himes B.E., Come C.E., D'Aco K., Martinez F.J., Han M.K., Lynch D.A., Crapo J.D., Morse D., Ryter S.W., Silverman E.K., Rosas I.O., Choi A.M., Hunninghake G.M., Investigators C.O. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am. J. Respir. Crit. Care Med. 2012, 185:547-556.
26. Massonnet B., Normand S., Moschitz R., Delwail A., Favot L., Garcia M., Bourmeyster N., Cuisset L., Grateau G., Morel F., Silvain C., Lecron J.C. Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human monocytes. Eur. Cytokine Netw. 2009, 20:112-120.
27. Lin Q., Li M., Fang D., Fang J., Su S.B. The essential roles of Toll-like receptor signaling pathways in sterile inflammatory diseases. Int. Immunopharmacol. 2011, 11:1422-1432.
28. Choi S.H., Harkewicz R., Lee J.H., Boullier A., Almazan F., Li A.C., Witztum J.L., Bae Y.S., Miller Y.I. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ. Res. 2009, 104:1355-1363.
29. Michelsen K.S., Doherty T.M., Shah P.K., Arditi M. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J. Immunol. 2004, 173:5901-5907.
30. Michelsen K.S., Wong M.H., Shah P.K., Zhang W., Yano J., Doherty T.M., Akira S., Rajavashisth T.B., Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10679-10684.
31. Barton G.M., Medzhitov R. Toll-like receptor signaling pathways. Science 2003, 300:1524-1525.
32. Tak P.P., Firestein G.S. NF-κB: a key role in inflammatory diseases. J. Clin. Invest. 2001, 107:7-11.
33. Hiscott J., Marois J., Garoufalis J., D'Addario M., Roulston A., Kwan I., Pepin N., Lacoste J., Nguyen H., Bensi G., et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol. Cell. Biol. 1993, 13:6231-6240.
34. Son Y.H., Jeong Y.T., Lee K.A., Choi K.H., Kim S.M., Rhim B.Y., Kim K. Roles of MAPK and NF-κB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 2008, 51:71-77.
35. Juliana C., Fernandes-Alnemri T., Wu J., Datta P., Solorzano L., Yu J.W., Meng R., Quong A.A., Latz E., Scott C.P., Alnemri E.S. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J. Biol. Chem. 2010, 285:9792-9802.